Evidence map›Paper›PMID 41756527›Full record

ArticleMaterials today. Bio2026

Ultrasound-propelled oncolytic biomimetic microbubbles as

Li Wan, Ping Liang, Chunyu Xia, Liliang Yu, Rui Tang, Xintong Li, Chenchen Tang, Nianhong Wu, Zeyan Huang, Jimei Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Li WanDepartment of Ultrasound, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Ping LiangDepartment of Ultrasound, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Chunyu XiaDepartment of Pharmacy, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Liliang YuChongqing Three Gorges Medical College, Chongqing, 404120, China.
Rui TangDepartment of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400042, China.
Xintong LiDepartment of Ultrasound, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Chenchen TangDepartment of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400042, China.
Nianhong WuChongqing Key Laboratory of Ultrasound Molecular Imaging, Institute of Ultrasound Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Zeyan HuangChongqing Key Laboratory of Ultrasound Molecular Imaging, Institute of Ultrasound Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Jimei ChenDepartment of Ultrasound, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Ruqian FuDepartment of Ultrasound, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Mingke JiaoDepartment of Ultrasound, The People's Hospital of Yubei District of Chongqing City, Chongqing, 401120, China.
Jie HuDepartment of Ultrasound, The People's Hospital of Yubei District of Chongqing City, Chongqing, 401120, China.
Pan LiDepartment of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400042, China.
Rui LiDepartment of Ultrasound, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic peptides offer a novel anticancer paradigm by inducing membrane lysis-mediated cancer cell death and subsequent anticancer immunity to overcome tumor heterogeneity and treatment resistance. Despite its promising profiles, the clinical application of oncolytic peptides (such as LTX-315) is hampered by ticklish reasons like rapid plasma clearance, suboptimal biodistribution, and potential toxicity toward normal tissues. Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy. The LCMBs enabled the targeted delivery and stimuli-responsive release of LTX-315 in the tumor site under low-intensity focused ultrasound (US). The high accumulation of LTX-315 and sonoporation-mediated membrane permeabilization collectively lowered the therapeutic threshold of LTX-315, improving oncolytic efficacy and reducing the off-target toxicity. LTX-315 further potentiated rapid membrane lysis and subsequent immunogenic cell death, promoting the release of tumor antigens, forming an

Indexed as

Homologous targetingImmunotherapyIn situ vaccinesLow-intensity focused ultrasoundOncolytic therapyTumor immunosuppressive microenvironment

Identifiers

PMID41756527
PMCPMC12933863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.